Lantheus Holdings (LNTH) Change in Accured Expenses (2014 - 2026)
Lantheus Holdings (LNTH) posted quarterly Change in Accured Expenses of $23.0 million for Q1 2026, up 591.23% year-over-year from $3.3 million in Q1 2025, and up 15.89% quarter-over-quarter from $19.8 million in Q4 2025.
Lantheus Holdings (LNTH) Change in Accured Expenses (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has reported Change in Accured Expenses for 13 consecutive years, with $23.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses rose 591.23% year-over-year to $23.0 million; the TTM figure through Mar 2026 stood at $10.6 million (up 3092.66% YoY), while the FY2025 annual figure was -$9.1 million, down 119.42% from the prior year.
- Change in Accured Expenses improved to $23.0 million in Q1 2026 per LNTH's latest filing, from $19.8 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $50.4 million in Q1 2024 and bottomed at -$123.8 million in Q2 2023.
- Historically, Change in Accured Expenses has averaged $2.5 million across 5 years, with a median of $8.1 million in 2023.
- Annual changes were most pronounced in 2023 — Change in Accured Expenses surged 1237.99% — and 2025, when it tumbled 1553.76%.
- Lantheus Holdings' Change in Accured Expenses stood at $33.2 million in 2022, then slumped by 75.66% to $8.1 million in 2023, then jumped by 249.39% to $28.2 million in 2024, then fell by 29.7% to $19.8 million in 2025, then advanced by 15.89% to $23.0 million in 2026.
- Business Quant data shows LNTH's Change in Accured Expenses at $23.0 million in Q1 2026, $19.8 million in Q4 2025, and -$26.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 82.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 142.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -219.00 Mn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | -4.00 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | -8.50 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Lantheus Holdings | 6.52 Bn | 5.93 Bn | 241.86 Mn | -1.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.99 Mn |
| Jun 30, 2026 | -1.99 Mn |
| Mar 31, 2026 | 23.00 Mn |
| Mar 31, 2026 | 23.00 Mn |
| Dec 31, 2025 | 19.85 Mn |
| Dec 31, 2025 | 19.85 Mn |
| Sep 30, 2025 | -26.31 Mn |
| Sep 30, 2025 | -26.31 Mn |
| Jun 30, 2025 | -5.95 Mn |
| Jun 30, 2025 | -5.95 Mn |
| Mar 31, 2025 | 3.33 Mn |
| Mar 31, 2025 | 3.33 Mn |
| Dec 31, 2024 | 28.24 Mn |
| Dec 31, 2024 | 28.24 Mn |
| Sep 30, 2024 | 1.81 Mn |
| Sep 30, 2024 | 1.81 Mn |
| Jun 30, 2024 | -33.73 Mn |
| Jun 30, 2024 | -33.73 Mn |
| Mar 31, 2024 | 50.45 Mn |
| Mar 31, 2024 | 50.45 Mn |